https://dergipark.org.tr/tr/pub/ijhmt Doi Number: 10.31201/ijhmt.1598478

Int Journal of Health Manag. and Tourism 2025, 10(1), 75-105

JHMT Editorial

International Journal of Health Management and Tourism

Innovative Strategies to Combat Antibiotic Resistance: Emerging Trends and Future Directions

Bahar SENEL*, Hayati BEKA**

* Istanbul University, Istanbul Faculty of Medicine, Department of Medical Microbiology, Istanbul, Turkiye, ORCID Number: 0000-0002-9175-6107

** Istanbul Arel Universty, Faculty of Medicine, Department of Clinical Microbiology, Istanbul, Turkiye,

ORCID Number 0000-0002-5509-0248

Received: 11.12.2024
Accepted: 06.02.2025
Review

Abstract

Aim: Antimicrobial resistance (AMR) represents a critical global health challenge exacerbated by the overuse and misuse of antibiotics in human, animal, and environmental contexts. This study aims to examine the barriers to addressing AMR, with a specific focus on scientific, economic, and regulatory challenges in the development and adoption of novel antimicrobial strategies.

Methods: This review synthesizes current literature on innovative therapeutic approaches, such as bacteriophage therapy and antimicrobial peptides, alongside an analysis of global policy initiatives, including the WHO Global Action Plan on AMR and the PASTEUR Act. Emphasis is placed on identifying key obstacles and potential solutions within the realms of antibiotic R&D and policy frameworks.

Corresponding author: Bahar SENEL, e-mail: baharkarli@gmail.com

Cite This Paper:
Senel, B., Beka, H. (2025). Innovative Strategies to Combat Antibiotic Resistance: Emerging Trends and Future Directions. *International Journal of Health Management and Tourism, 10(1): 75-105.*

Results: Findings highlight the significant promise of alternative therapies and policy-driven incentives to address AMR. However, limitations such as scientific hurdles, economic disincentives, and disparities in regulatory enforcement hinder progress. Novel policy measures like subscription-based models and improved diagnostic tools have shown potential to close existing gaps.

Conclusion: Collaborative global efforts are essential to address AMR effectively. Sustainable funding mechanisms, advanced diagnostic technologies, and integrated One Health approaches must be prioritized to bridge gaps between science, policy, and practice. By addressing these challenges, the global community can mitigate the escalating threat of AMR and safeguard the efficacy of antibiotics for future generations.

Keywords: Antimicrobial resistance, antibiotic development, global health, One Health, policy initiatives

INTRODUCTION

Antibiotic resistance is one of the most critical threats to global public health, undermining decades of progress in treating infectious diseases. The discovery of antibiotics in the early 20th century revolutionized medicine, transforming once-lethal infections into treatable conditions (Ventola, 2015). However, the misuse and overuse of antibiotics in healthcare, agriculture, and aquaculture have contributed to the selection and proliferation of resistant microorganisms, creating a global crisis (Laxminarayan et al., 2013).

Globally, antibiotic-resistant infections are responsible for an estimated 1.27 million direct deaths annually, with nearly 5 million more deaths associated with resistance-related complications (Murray et al., 2022). These staggering numbers highlight the scale of the issue, which disproportionately affects low- and middle-income countries (LMICs) due to limited access to healthcare, diagnostics, and effective antibiotic stewardship programs (Dunachie ,2020; Iskandar 2021). Even in high-income countries, resistant infections impose significant economic burdens, with the annual cost of antibiotic resistance in the U.S. alone estimated to exceed $20 billion in direct healthcare expenses (Prestinaci, 2015).

In addition to these global challenges, countries like Turkey have made substantial efforts to address AMR through national policies and programs. The Turkish Ministry of Health has introduced initiatives such as the "Rational Drug Use Action Plan," which emphasizes public education, physician training, and strict regulations on antibiotic prescriptions (Turkish Ministry of Health, 2023). Restricting the authorization of family physicians to prescribe certain antibiotics has been a notable policy, leading to a measurable decline in antibiotic misuse. Furthermore, the National Antimicrobial Resistance Surveillance System (NAMRSS) has played a pivotal role in tracking resistance patterns and informing public health strategies (Alkan et al., 2022). Studies in Turkey have highlighted alarming levels of resistance, particularly in hospital settings, where carbapenem-resistant Klebsiella pneumoniae and extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli are significant concerns (Demirci et al., 2021). These findings underscore the importance of integrating national efforts with global frameworks to combat AMR effectively.

The Rise of Resistance

Bacteria develop resistance through intrinsic and acquired mechanisms, including efflux pumps, enzymatic degradation of antibiotics, target site modifications, and horizontal gene transfer (Martínez et al., 2015). Notably, the spread of resistance genes, such as extended-spectrum β-lactamases (ESBLs) and carbapenemases, has rendered many frontline and even last-resort antibiotics ineffective (Bush and Bradford, 2020). Compounding the issue, the environmental dissemination of antibiotic resistance genes (ARGs) has established reservoirs of resistance in natural ecosystems, further accelerating the crisis (Berendonk et al., 2015).

The overuse of antibiotics in agriculture plays a significant role in this dynamic. Antibiotics are commonly used in livestock to prevent disease and promote growth, practices that contribute to the selection of resistant strains and their subsequent transmission to humans through food, water, and the environment (Van Boeckel et al., 2017). For example, colistin, a last-resort antibiotic in human medicine, has been widely used in animal agriculture, leading to the emergence of plasmid-mediated mcr-1 resistance, which has now been detected globally (Liu et al., 2016).

Challenges in Antibiotic Development

The development of new antibiotics faces numerous scientific, economic, and regulatory challenges that hinder the ability to effectively combat AMR.

Scientific Barriers

The discovery of novel antibiotic classes has slowed significantly, with no major breakthroughs in recent decades. Most antibiotics are derived from natural sources such as soil microbes, and many easily accessible compounds have already been explored. The discovery process is further complicated by the need to identify molecules with activity against resistant pathogens while avoiding toxicity to human cells (Lewis, 2020). Additionally, resistance mechanisms, including efflux pumps and biofilm formation, reduce the efficacy of potential drug candidates, complicating the development pipeline further (Ventola, 2015).

Economic Disincentives

Pharmaceutical companies are often reluctant to invest in antibiotic research and development (R&D) due to poor financial returns. Unlike medications for chronic diseases, antibiotics are typically prescribed for short durations, limiting profitability (Rex et al., 2016). Stewardship programs, though essential for controlling AMR, discourage the widespread use of new antibiotics, further diminishing revenue prospects (Balasegaram et al., 2021). The estimated cost of developing a single antibiotic can exceed $1 billion, with a low probability of market success, prompting many major pharmaceutical companies to exit the field (Silver, 2011).

Regulatory Challenges

Antibiotic development is subject to stringent regulatory standards designed to ensure safety and efficacy. However, these processes are time-consuming and costly. Demonstrating efficacy against multidrug-resistant pathogens requires complex clinical trials, which often involve small patient populations, making recruitment and statistical analysis difficult (Ventola, 2015). Furthermore, the regulatory landscape lacks flexibility for alternative approaches, such as bacteriophage therapy or antimicrobial peptides, further stalling innovation in the field (Cassini et al., 2019).

Addressing the Challenges

The challenges facing the development of new antibiotics are multifaceted, ranging from scientific barriers to economic and regulatory hurdles. These challenges require coordinated, multifactorial approaches to overcome. Efforts to address these barriers have focused on incentivizing innovation, streamlining regulatory processes, and increasing global collaboration.

Scientific Barriers and Innovation Incentives

The slowdown in the discovery of novel antibiotic classes has been attributed to several scientific factors. As traditional sources of antibiotics, such as soil bacteria, have been exhausted, researchers are increasingly exploring alternative strategies like synthetic biology and the use of natural compounds from unexplored ecosystems (Lewis, 2020). To overcome these scientific barriers, there is a call for greater investment in novel discovery platforms. One such initiative is the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X), which supports early-stage antibiotic research (Blaskovich, 2020). This initiative and similar programs offer financial incentives to smaller biotech firms that are developing innovative antibiotics, addressing the gap left by major pharmaceutical companies' retreat from antibiotic R&D due to economic disincentives (Outterson, 2016).

Economic Challenges and Regulatory Incentives

The economic challenges of antibiotic development stem from the low profitability associated with antibiotics. Unlike chronic disease medications, antibiotics are typically used for short durations and often within specific contexts, limiting their market potential (Rex, 2016). This has led to a significant reduction in antibiotic R&D by large pharmaceutical companies. To address this, there have been proposals such as the PASTEUR Act, which seeks to create financial incentives through subscription-based models for antibiotic developers (Piddock, 2024). These models offer upfront payments to companies for the development of new antibiotics, ensuring that they have sufficient financial motivation to invest in this crucial area.

Additionally, regulatory pathways for antibiotic approval have been critiqued for being lengthy and costly, often resulting in delayed access to new treatments. To improve this process, regulatory agencies such as the U.S. Food and Drug Administration (FDA) have worked to streamline approval processes for antibiotics targeting serious and resistant infections, such as through the Limited Population Pathway for Antibacterial and Antifungal Drugs (FDA, 2020). This pathway aims to accelerate approval for antibiotics with limited indications, ensuring quicker access to drugs needed in urgent situations.

Collaborative Efforts

A crucial part of addressing these challenges lies in fostering greater global collaboration. Public-private partnerships, like the Global Antibiotic Research and Development Partnership (GARDP), have been pivotal in driving innovation in antibiotic development, particularly for neglected diseases (WHO, 2019). These partnerships help bridge the funding gap, foster international research, and provide a platform for the global sharing of knowledge and resources.

Efforts are also being made to improve collaboration among governments, academic institutions, and private industry. Governments are increasingly involved in funding basic research, while pharmaceutical companies are being encouraged to participate in open-source research models to accelerate antibiotic discovery. Additionally, initiatives like the Fleming Fund provide crucial support for AMR surveillance and capacity-building efforts in low-income countries, where the threat of resistant infections is often most pronounced (Chinemerem et al., 2022).

Emerging Solutions

Given these challenges, researchers and policymakers have shifted their focus to innovative approaches for combating resistance. Antimicrobial stewardship programs (ASPs) aim to optimize antibiotic use, ensuring appropriate prescriptions while minimizing unnecessary exposure to these drugs (Sirwan et al., 2024). Rapid diagnostic tools, such as next-generation sequencing (NGS) and CRISPR-based assays, enable timely and precise identification of pathogens, allowing for targeted treatments that reduce selective pressure on bacteria (Chen et al., 2018).

Alternative therapies are also gaining traction as potential solutions. Bacteriophage therapy, which uses viruses that specifically target and kill bacteria, offers a promising avenue for treating multidrug-resistant infections (Abdulaziz, 2023). Similarly, antimicrobial peptides—short, naturally occurring proteins with broad-spectrum antibacterial activity—are being investigated as potential adjuncts or replacements for conventional antibiotics (Shuaiqi et al., 2023).

Global Policy Initiatives

AMR represents a global challenge requiring coordinated policy responses across regions and sectors. International organizations and national governments have recognized the urgency of this issue, launching various initiatives to address it. Central to these efforts is the World Health Organization's (WHO) Global Action Plan on Antimicrobial Resistance (WHO, 2015). This comprehensive framework adopts a One Health approach, emphasizing the interconnectedness of human, animal, and environmental health. The plan outlines five strategic objectives, including improving awareness, enhancing surveillance, optimizing antimicrobial use, and promoting sustainable investment in new medicines and diagnostic tools (WHO, 2015).

Regional efforts complement the WHO's work. For instance, the European Union's (EU) Joint Programming Initiative on Antimicrobial Resistance (JPIAMR) supports transnational research and surveillance systems to address AMR. This program fosters collaboration among EU member states, focusing on understanding resistance mechanisms, improving diagnostics, and exploring alternative treatments (Fitchett and Altun, 2015). In addition, the Fleming Fund, supported by the UK government, provides funding to LMICs to strengthen their capacities in AMR surveillance and laboratory testing (Ribeiro et al., 2019).

Global initiatives have also targeted economic drivers of resistance. The Global Antibiotic Research and Development Partnership (GARDP), a joint venture between the WHO and the Drugs for Neglected Diseases Initiative (DNDi), focuses on developing affordable, accessible treatments for resistant infections (Simpkin et al., 2017).

Despite these advancements, challenges persist. Disparities in funding and infrastructure between high-income and LMICs hinder the implementation of global policies. For example, while high-income nations have made strides in developing rapid diagnostics and promoting stewardship programs, many LMICs lack the resources for even basic infection prevention and control measures. Regulatory weaknesses also impede the enforcement of AMR-related policies, particularly in regions with unregulated antibiotic sales and use (Van Boeckel et al., 2014).

To bridge these gaps, policy initiatives must prioritize equitable resource distribution and capacity building. Strengthening global partnerships, such as those between the WHO, the Food and Agriculture Organization (FAO), and the World Organisation for Animal Health (OIE), is critical. These collaborations can drive progress in areas like harmonizing AMR surveillance methods and setting global standards for antibiotic use in agriculture (Wernli et al., 2020). Moreover, the establishment of financial incentives for pharmaceutical companies to invest in antibiotic research could address the stagnation in antibiotic development (Simpkin, 2017).

In summary, while global policy initiatives have laid a strong foundation for combating AMR, sustained commitment and innovation are necessary to address existing barriers. Enhanced international cooperation, along with tailored strategies for diverse socio-economic contexts, is essential to ensure the effectiveness of these efforts. Only through a unified and sustained approach can the global community mitigate the impact of AMR on health systems, economies, and societies.

1. RESEARCH METHODOLOGY

This review adopts a structured methodology to synthesize current knowledge and provide a comprehensive analysis of innovative strategies addressing antibiotic resistance. The approach is grounded in systematic literature review principles, encompassing the identification, selection, and analysis of peer-reviewed articles, guidelines, and reports from reputable sources. The following steps outline the methodology employed:

1.1. Literature Search Strategy

A systematic search was conducted across major academic databases, including PubMed, Scopus, Web of Science, and Google Scholar, to identify relevant literature published between 2010 and 2024. Keywords and Boolean operators were applied to capture a broad spectrum of studies related to antibiotic resistance and emerging mitigation strategies. The primary search terms included:

- “antibiotic resistance” AND “innovative strategies”
- “alternative therapies” AND “antimicrobial peptides”
- “bacteriophage therapy” OR “phage therapy”
- “antimicrobial stewardship programs”
- “rapid diagnostics” AND “antibiotic resistance”
- “antibiotic resistance genes” OR “ARGs”

The search was supplemented by manual screening of reference lists in selected articles to identify additional relevant publications.

1.2. Inclusion and Exclusion Criteria

To ensure the relevance and quality of included studies, the following inclusion and exclusion criteria were applied:

Inclusion Criteria:

- Peer-reviewed articles, systematic reviews, and meta-analyses.
- Studies published in English between 2010 and 2024.
- Research addressing innovative solutions, mechanisms, or policy interventions targeting antibiotic resistance.
- Articles providing quantitative or qualitative evaluations of novel strategies.

Exclusion Criteria:

- Non-English publications.
- Studies focused solely on traditional antibiotics without discussing resistance or mitigation strategies.
- Conference abstracts and opinion pieces lacking empirical data.

1.3. Data Extraction

Data from the selected studies were systematically extracted into a predefined template. The following information was recorded for each article:

- Title and year of publication.
- Study type (e.g., experimental, observational, or review).

- Key findings related to innovative approaches such as bacteriophage therapy, antimicrobial peptides, rapid diagnostics, and stewardship programs.
- Outcomes and limitations discussed in each study.

1.4. Quality Assessment

The quality of the included studies was evaluated using established criteria such as the Critical Appraisal Skills Programme (CASP) checklist. Each study was assessed for its methodology, sample size, reproducibility, and the reliability of reported outcomes. Low-quality studies were excluded to maintain the rigor of the review.

1.5. Analytical Framework

The extracted data were synthesized using a thematic analysis framework. Studies were grouped into the following thematic categories based on their focus:

- **Therapeutic Innovations:** Examination of novel treatments like bacteriophage therapy, antimicrobial peptides, and alternative drug delivery mechanisms.
- **Diagnostic Advancements:** Analysis of rapid diagnostic tools, including CRISPR-based systems and next-generation sequencing technologies.
- **Policy and Stewardship Initiatives:** Evaluation of global and regional antimicrobial stewardship programs, as well as policy frameworks aimed at reducing resistance.

Key findings were compared and contrasted to identify trends, gaps, and areas requiring further research.

1.5.1. Enhancing Methodological Rigor

Detailed Reporting of Study Selection and Data Extraction

A common limitation in systematic reviews is the insufficient detail provided in the study selection and data extraction processes. To enhance transparency and reproducibility, it is essential to clearly define inclusion and exclusion criteria, outline the search strategy comprehensively, and describe the data extraction methods in detail. Following established methodological guidance, such as the CoCoPop mnemonic (Condition, Context, and Population), can aid in structuring these processes effectively (Woldegeorgis, et.,al 2023)

Addressing Sampling Bias and Ensuring Representativeness

Sampling bias poses a significant threat to the validity of AMR studies. Studies often rely on convenience samples, which may not accurately represent the broader population. Implementing strategies to minimize sampling bias, such as random sampling and ensuring diverse participant recruitment across different settings and demographics, can improve the representativeness of the findings (Iskandar, et., al 2021).

Comprehensive Assessment of Data Quality

The reliability of AMR studies heavily depends on the quality of the data collected. It is imperative to assess data sources for completeness, accuracy, and consistency. Utilizing standardized data collection tools and protocols can enhance data quality. Additionally, acknowledging and addressing potential limitations in data sources, such as underreporting or misclassification, is crucial for accurate interpretation (Schnall, et., al 2019)

Incorporation of Advanced Analytical Methods

Employing advanced statistical and analytical methods can provide deeper insights into AMR trends and determinants. Techniques such as meta-analysis, sensitivity analysis, and modeling can help in understanding the variability and robustness of the results. However, it is essential to ensure that these methods are appropriately applied and that their assumptions are met to avoid misleading conclusions (Painter, et., al 2023)

Transparent Reporting of Limitations and Potential Biases

A critical aspect of methodological rigor is the transparent reporting of a study's limitations and potential biases. Clearly discussing these aspects allows for a better assessment of the study's validity and facilitates the interpretation of the findings within the appropriate context. This practice also aids in identifying areas for future research and improvement (McCubbin, et., al 2021).

By implementing these methodological enhancements, AMR research can achieve more reliable and generalizable outcomes, ultimately contributing to more effective strategies in combating AMR**.**

2. ANALYSIS

The global antibiotic resistance crisis necessitates innovative solutions that address its multifaceted nature, spanning therapeutic interventions, diagnostic advancements, and policy-driven stewardship programs. This section critically examines the emerging strategies aimed at combating antibiotic resistance, analyzing their mechanisms, effectiveness, limitations, and potential for widespread implementation.

2.1. Therapeutic Innovations

2.1.1. Bacteriophage Therapy

Bacteriophage therapy has garnered attention as a viable alternative to traditional antibiotics. Phages are viruses that selectively infect and lyse bacterial cells, offering a targeted approach to combat resistant pathogens. Unlike broad-spectrum antibiotics, phages can be engineered to target specific bacterial strains, minimizing off-target effects and preserving the host microbiota (Cisek et al., 2017).

Recent clinical trials have demonstrated the efficacy of phage therapy in treating multidrug-resistant *Pseudomonas aeruginosa* and *Acinetobacter baumannii* infections (Chan et al., 2018). However, limitations include the potential for bacterial resistance to phages and regulatory hurdles associated with personalized phage cocktails (Lin et al., 2022). Despite these challenges, advancements in synthetic biology are enabling the development of engineered phages with enhanced lytic activity and broader applicability (Sun, 2013).

2.1.2. Antimicrobial Peptides (AMPs)

Antimicrobial peptides represent another promising avenue. These naturally occurring molecules disrupt bacterial membranes and exhibit broad-spectrum activity against both Gram-positive and Gram-negative bacteria (Hancock et al., 2016). Their mechanism of action reduces the likelihood of resistance development compared to traditional antibiotics. Studies have identified AMPs such as colistin and daptomycin as effective against carbapenem-resistant *Enterobacteriaceae* (CRE) and vancomycin-resistant *Enterococci* (VRE) (Garvey, 2023). However, the high cost of production and potential toxicity remain significant barriers to their widespread clinical use. Recent innovations in AMP design and delivery systems aim to mitigate these issues, enhancing their stability and therapeutic index (Verma et al., 2024).

2.1.3. Anti-Virulence Therapies

Anti-virulence therapies focus on neutralizing bacterial virulence factors, such as toxins, adhesion molecules, and biofilm-forming proteins, without exerting selective pressure on bacterial growth (Fleitas et al., 2019). This approach minimizes the risk of resistance development while disarming pathogens. Examples include quorum-sensing inhibitors and monoclonal antibodies targeting bacterial exotoxins (Battah and Donadu, 2024). Despite their potential, anti-virulence strategies are still in early developmental stages, and their clinical efficacy in complex infections remains under investigation (Kong et al., 2016).

2.2. Diagnostic Advancements

2.2.1. Rapid Diagnostic Tools

Rapid diagnostics play a pivotal role in combating antibiotic resistance by enabling precise identification of pathogens and their resistance profiles. Techniques such as polymerase chain reaction (PCR), next-generation sequencing (NGS), and CRISPR-based diagnostics allow for faster and more accurate detection compared to traditional culture methods (Van Belkum et al., 2019).

For example, NGS-based approaches can identify resistance genes in bacterial genomes within hours, guiding clinicians in selecting appropriate therapies (Ellington et al., 2017). CRISPR-based tools, such as SHERLOCK and DETECTR, have shown promise in detecting resistance markers with high sensitivity and specificity (Mustafa and Makhavi, 2024). However, the high cost and limited accessibility of these technologies in resource-limited settings pose significant challenges to their global implementation.

2.2.2. Point-of-Care Testing

Point-of-care (POC) diagnostic tests are particularly valuable in LMICs, where laboratory infrastructure may be limited. These portable devices, often based on immunoassays or nucleic acid amplification, provide rapid results at the patient's bedside (Boehme, 2010). Advances in microfluidics and lab-on-a-chip technologies are improving the accuracy and affordability of POC tests, making them a critical component of global antimicrobial stewardship efforts (Chin et al., 2011).

2.3. Policy and Stewardship Initiatives

2.3.1. Antimicrobial Stewardship Programs (ASPs)

ASPs are critical in optimizing the use of antibiotics in clinical settings to reduce the overuse and misuse of these essential medicines. By ensuring that antibiotics are prescribed only when necessary, and that the right antibiotic is selected for the appropriate duration, ASPs mitigate the selective pressure that drives the development of AMR (Sirvan et al., 2024). These programs rely on multidisciplinary teams, including infectious disease specialists, pharmacists, microbiologists, and other healthcare professionals, to implement evidence-based prescribing practices and monitor antibiotic use (Van Dijck et al., 2018). This collaborative approach has been shown to significantly improve antibiotic prescribing habits, leading to reductions in inappropriate prescriptions, which in turn helps to prevent the emergence of resistant pathogens.

Studies have demonstrated that ASPs can reduce antibiotic consumption by up to 30% without negatively affecting patient outcomes, highlighting their effectiveness in curbing AMR. For example, a study conducted across various hospital settings found that ASPs led to a reduction in broad-spectrum antibiotic use and a decrease in the incidence of hospital-acquired infections (Davey et al., 2017). Furthermore, ASPs have been shown to be cost-effective, offering financial savings for healthcare systems by reducing the need for prolonged hospital stays due to antibiotic-resistant infections (Schuts et al., 2016).

However, the success of these programs is contingent on several factors, including strong institutional support, continuous education of healthcare providers, and the availability of timely diagnostic tools. Hospitals and healthcare systems must invest in staff training and infrastructure to ensure that ASPs are effectively implemented. The availability of rapid diagnostic technologies is also crucial, as they enable clinicians to identify the most appropriate antibiotic therapy more quickly, thus improving the overall efficiency of the stewardship program (Van Santen et al., 2022).

2.3.2. Policy Frameworks and Global Action Plans

AMR is a pressing global health challenge that demands coordinated efforts across regions and sectors. Recognizing this, international organizations like the World Health Organization (WHO) have developed strategic frameworks to address the issue. The WHO Global Action Plan on Antimicrobial Resistance (WHO, 2015) emphasizes a comprehensive "One Health" approach that integrates human, animal, and environmental health. This approach acknowledges that resistance in one sector (e.g., veterinary or agriculture) can contribute to the spread of resistant pathogens across all areas, including healthcare settings. The plan outlines key objectives to combat AMR: raising awareness, improving surveillance, optimizing antimicrobial use, and promoting the development of new treatments and diagnostics (WHO, 2015). This holistic perspective is essential to tackling the multi-faceted drivers of AMR, as resistance is not confined to clinical environments but spans the entire ecosystem.

National and regional initiatives also play a significant role in combating AMR. Programs such as the Fleming Fund—which focuses on strengthening surveillance and laboratory capacities in LMICs —and the European Joint Programming Initiative on Antimicrobial Resistance

(JPIAMR), which coordinates international research funding and prioritizes AMR research, further enhance global efforts. These programs are crucial for improving surveillance, building research capacity, and ensuring the availability of timely data on the prevalence of resistant pathogens (Chinemerem et al., 2022). The Fleming Fund, for instance, has focused on improving diagnostic and surveillance infrastructure in countries where AMR is a rapidly growing problem, while JPIAMR helps unify research efforts across Europe to create sustainable solutions.

Despite these efforts, disparities in resource allocation and regulatory enforcement persist. Many low-income countries still face challenges in implementing effective AMR policies due to limited funding and infrastructure. Moreover, differences in regulatory approaches, such as inconsistent antimicrobial stewardship practices and inadequate enforcement of veterinary antibiotic use regulations, hinder the success of AMR strategies globally. To be effective, these frameworks must be implemented equitably, with particular attention to the needs of LMICs that are disproportionately affected by AMR.

These challenges highlight the need for stronger global partnerships, improved policy coherence, and greater financial commitments to support AMR programs worldwide. Only through sustained collaboration and increased investments can the global community hope to mitigate the threat of AMR and safeguard the efficacy of antibiotics for future generations.

2.3.3. Strengthening Practical Applications in AMR

AMR poses a significant threat to global health, particularly in LMICs. Implementing practical, context-specific strategies is crucial to mitigate this challenge effectively. Below are real-world examples and case studies illustrating successful AMR mitigation efforts in LMICs.

Community-Based Antimicrobial Stewardship Programs

Community-driven ASPs have demonstrated success in reducing inappropriate antibiotic use in rural and underserved areas. For instance, in the South Indian state of Kerala, a comprehensive strategy was implemented to prioritize infection prevention and control, alongside antimicrobial stewardship. This approach led to a significant reduction in antibiotic misuse and highlighted the importance of tailored interventions in LMICs (Singh, et., al 2021).

Integrating Rapid Diagnostics into Primary Care

The integration of rapid diagnostic tools into primary healthcare settings has proven effective in guiding appropriate antibiotic use. In Bangladesh, a scoping review examined hospital-based ASPs, shedding light on barriers and facilitators to effective implementation. The study emphasized the need for rapid diagnostics to improve antibiotic prescribing practices, ultimately contributing to better patient outcomes (Harun, et., al 2024).

Public-Private Partnerships for Sustainable Interventions

Public-private partnerships (PPPs) can drive sustainable AMR interventions by pooling resources and expertise. In South Africa, collaborative efforts between governmental bodies and private organizations have been pivotal in addressing AMR challenges. These partnerships have facilitated the development and distribution of low-cost diagnostic tools and have supported public health campaigns aimed at reducing antibiotic misuse (Pokharel, et al., 2019).

Promoting Local Innovations in LMICs

Encouraging local innovation is critical to addressing AMR in resource-constrained settings. In various LMICs, community-led initiatives have empowered small-scale farmers to adopt alternative livestock health practices, such as the use of probiotics and vaccination programs, thereby reducing reliance on antibiotics. These grassroots efforts have been instrumental in decreasing antibiotic use in agriculture and mitigating the spread of resistance (Rony, et., al 2023)

Recommendations for Future Implementation

Field-Based Research: Invest in studies that evaluate the effectiveness of AMR strategies within specific local contexts, considering cultural, social, and economic factors.

Capacity Building: Provide training and resources for healthcare workers and community leaders to implement and sustain AMR programs effectively.

Policy Support: Encourage governments to adopt evidence-based policies that incentivize the use of alternatives to antibiotics in agriculture and healthcare.

Monitoring and Evaluation: Establish robust mechanisms to track the outcomes of implemented strategies, ensuring continuous improvement and scalability.

By leveraging these real-world examples and recommendations, stakeholders can bridge the gap between policy and practice, ensuring that global AMR initiatives deliver tangible benefits across diverse settings.

2.3.4. Localized Strategies for Addressing AMR in LMICs

Addressing AMR necessitates the implementation of localized strategies that consider the unique cultural, economic, and healthcare contexts of LMICs. Tailoring interventions to local needs can enhance their effectiveness and sustainability.

Strengthening Healthcare Infrastructure

Improving healthcare infrastructure is fundamental in combating AMR. Enhancements in water, sanitation, and hygiene (WASH) within healthcare facilities can significantly reduce infection rates, thereby diminishing the need for antibiotics. WHO emphasizes that inadequate WASH conditions in LMICs exacerbate the spread of infections, contributing to increased antibiotic consumption and resistance (WHO, 2023).

Implementing Effective Regulatory Frameworks

Enforcing robust regulatory frameworks ensures the appropriate use of antimicrobials. A study analyzing antimicrobial stewardship policies reported that 67% of surveyed countries had a national action plan on AMR, and 64% had legislative policies on antimicrobial use. However, the effectiveness of these policies varies, highlighting the need for context-specific regulations that address local challenges (Zay Ya et al., 2024).

Enhancing Diagnostic Capabilities

Investing in diagnostic technologies enables accurate and timely identification of infections, facilitating appropriate antimicrobial use. The application of data technologies, such as artificial intelligence and machine learning, in diagnostics has shown promise in improving AMR management. However, the integration of these technologies in LMICs faces challenges, including limited resources and technical expertise (Chindelevitch, et., al 2022).

Expanding Preventive Interventions

Preventive measures, including vaccination programs and public health campaigns, reduce the incidence of infections, thereby decreasing the reliance on antibiotics. For instance, mass drug administration of azithromycin in certain high-mortality regions has been associated with reduced child mortality rates. However, this approach must be balanced against the potential risk of promoting antibiotic resistance (Financial Times, 2023).

Educating Healthcare Providers and the Public

Education initiatives targeting healthcare providers and the public promote awareness of appropriate antimicrobial use. Training programs for healthcare workers on antimicrobial stewardship and public campaigns to inform communities about the dangers of misuse are essential components of a comprehensive AMR strategy (Kanan, et., al 2023).

By implementing these localized strategies, LMICs can effectively combat AMR, ensuring that interventions are culturally appropriate and sustainable within their specific contexts.

2.4. Environmental Considerations

The environmental reservoirs of antibiotic resistance represent a critical and often under-addressed facet of the AMR crisis. The widespread discharge of antibiotics, along with resistant bacteria, into natural ecosystems—such as water sources, soils, and sediments—accelerates the emergence and spread of resistance. These environmental pathways facilitate the transmission of resistant genes to human and animal populations, exacerbating the global burden of AMR (Berendonk et al., 2015). Antibiotics are released into the environment through various means, including improper disposal, agricultural runoff, and wastewater discharge from hospitals and pharmaceutical manufacturing plants (Martínez, 2009). This environmental contamination not only promotes the proliferation of resistant bacteria but also provides a reservoir for resistance genes that can be transferred across microbial species through horizontal gene transfer.

Efforts to mitigate environmental dissemination of antibiotic resistance are critical in reducing the global spread of AMR. One key approach is the improvement of wastewater treatment processes, which can help reduce the release of antibiotics and resistant bacteria into natural water systems. Advanced treatment technologies, such as membrane filtration and ozonation, have been found to be more effective in removing antibiotics and resistant microbes from wastewater (Kalli et al., 2023). Regulatory measures aimed at the pharmaceutical industry also play a vital role, including the implementation of stricter regulations on the disposal and manufacturing of antibiotics. Policies designed to minimize the environmental impact of pharmaceutical production, such as the European Union's Water Framework Directive, have been pivotal in reducing the release of pharmaceutical pollutants (Milmo, 2019).

Another promising solution is the development of biodegradable antibiotics. These are antibiotics designed to degrade naturally in the environment, reducing the persistence of resistance-promoting compounds in ecosystems (Michael, 2013). The focus on designing antibiotics with a minimal environmental footprint reflects the growing understanding that tackling AMR requires a holistic approach, considering not only clinical settings but also the broader environmental context. Additionally, the use of environmental monitoring systems to track the presence of antibiotics and resistant bacteria in water sources, soils, and sediments is vital for understanding the full extent of the environmental contribution to AMR (Panovska and Hajrulai-Musliu, 2024)

Incorporating environmental factors into global AMR policies is crucial for addressing the root causes of resistance. Efforts to control environmental pollution, coupled with stricter regulations and the development of environmentally friendly antibiotics, are integral components of the broader strategy to combat AMR. These measures require international collaboration and policy alignment to ensure a comprehensive and effective response to the rising threat of AMR.

3. CONCLUSIONS/ DISCUSSION AND RECOMMENDDATIONS

Antibiotic resistance (AR) has emerged as a critical threat to global health, with far-reaching implications for the treatment of infectious diseases. The rapid increase in resistant pathogens not only challenges medical practices but also places enormous strain on healthcare systems. While several innovative strategies have been proposed to combat AR, significant barriers remain in their widespread implementation, especially in resource-limited settings.

AMR is often framed as a biomedical challenge, it is fundamentally influenced by social and cultural factors. Healthcare accessibility, cultural perceptions of illness, and traditional beliefs about medicine shape how antibiotics are used within communities. Understanding these influences is crucial for designing effective ASPs and other intervention strategies that are tailored to specific populations.

Health literacy levels within communities play a critical role in the appropriate use of antibiotics. Low health literacy often leads to the misuse or overuse of antibiotics. In certain regions, there is a widespread misconception that antibiotics are effective against viral infections such as the common cold. Such misinformation contributes significantly to the rise of antibiotic resistance (Dogan, et., al 2021).

Cultural norms and traditions also shape antibiotic use. In some societies, there is a strong tendency to resort to medication at the first sign of illness. Moreover, in areas where antibiotics can be obtained without a prescription, individuals may self-medicate, leading to improper dosages and treatment durations (Ilhan, et., al 2019).

Social factors, such as access to healthcare and economic conditions, further impact antibiotic use. In regions with limited healthcare access, people often turn to alternative and frequently inappropriate treatment methods. Economic hardships drive individuals toward cheaper and more readily available antibiotics, increasing the risk of misuse (Bolsoy, et., al 2006).

One of the primary strategies in the fight against antibiotic resistance is the optimization of antibiotic use, particularly through ASPs. These programs have shown promising results in reducing unnecessary antibiotic prescriptions without compromising patient outcomes (Barlam et al., 2016). Evidence suggests that ASPs can reduce antibiotic consumption by up to 30% (Baur et al., 2017), contributing to decreased resistance rates. However, the success of these programs hinges on institutional support, continuous education, and the availability of diagnostic tools (Dyar et al., 2017). Moreover, the implementation of ASPs can be hindered by the lack of trained personnel and diagnostic infrastructure, especially in LMICs.

Rapid diagnostic tools have emerged as another essential component in combating antibiotic resistance. Techniques such as next-generation sequencing (NGS) and CRISPR-based diagnostics allow for quicker and more accurate pathogen identification, enabling targeted treatment and minimizing the unnecessary use of antibiotics (Didelot et al., 2016; van Belkum et al., 2019). These advancements hold the potential to transform clinical practice by ensuring more precise treatments. However, their high cost and limited accessibility in resource-poor settings pose significant challenges to global implementation (Chen et al., 2018; Okeke et al., 2011). This highlights the need for sustainable solutions that can bridge the gap between high- and low-resource settings.

As traditional antibiotics become less effective, alternative therapies are being explored. Antimicrobial peptides (AMPs), bacteriophage therapy, and anti-virulence strategies are gaining attention for their potential to address multidrug-resistant infections. AMPs such as colistin and daptomycin have shown efficacy against resistant pathogens, including carbapenem-resistant Enterobacteriaceae (CRE) and vancomycin-resistant Enterococci (VRE) (Magana et al., 2020; Lei et al., 2019). However, the high cost of production and potential toxicity of these therapies remain significant barriers to their widespread use (Magana et al., 2020).

Bacteriophage therapy, which uses viruses that target specific bacteria, has emerged as a promising alternative to antibiotics for treating multidrug-resistant infections (Czaplewski et al., 2016). Phage therapy's main advantage lies in its ability to specifically target bacterial pathogens, reducing the risk of broad-spectrum resistance development (Pirnay et al., 2019). Nevertheless, regulatory hurdles and bacterial resistance to phages pose challenges for its clinical use (Pirnay et al., 2019). Advances in synthetic biology and engineered phages may help overcome some of these limitations, making phage therapy a more viable option (Nobrega et al., 2018).

Anti-virulence therapies, which focus on neutralizing bacterial virulence factors, such as toxins and biofilm-forming proteins, are another promising area of research (Allen et al., 2014). These therapies aim to disarm pathogens without exerting selective pressure on bacterial growth, thus minimizing the risk of resistance development (LaSarre & Federle, 2013). While anti-virulence strategies hold great potential, their clinical efficacy remains under investigation (Maura et al., 2016), and further research is needed to validate their long-term effectiveness in complex infections.

International organizations, such as the World Health Organization (WHO), have recognized the urgent need for coordinated global efforts to tackle antibiotic resistance. The WHO Global Action Plan on Antimicrobial Resistance emphasizes a One Health approach, integrating human, animal, and environmental health to reduce resistance drivers (WHO, 2015). This approach is crucial given the interconnectedness of human, animal, and environmental health, where resistance can spread through various pathways, including food production, wastewater, and wildlife. National initiatives like the Fleming Fund and the European Joint Programming Initiative provide essential support for surveillance, research, and capacity building, but challenges such as disparities in resource allocation and regulatory enforcement persist (Ventola, 2015).

Environmental contamination with antibiotics and resistant bacteria represents an often-overlooked source of AR dissemination. Wastewater treatment improvements, stricter pharmaceutical manufacturing regulations, and the development of biodegradable antibiotics are critical strategies to reduce the environmental spread of resistance (Smith and Team, 2023). Addressing these environmental reservoirs requires coordinated global efforts and substantial investment in infrastructure and research.

Given the multifaceted challenges of AMR, a combination of strategic interventions is necessary to mitigate its impact. Based on the findings discussed above, the following recommendations are proposed to enhance antimicrobial stewardship, address social and cultural barriers, and improve healthcare accessibility in resource-limited settings.

Education and Awareness: Organize educational programs to improve community health literacy and provide accurate information on the appropriate use of antibiotics.

Culturally Adapted Policies: Develop health policies that take into account cultural norms and beliefs, involving community leaders and influencers in the process.

Improving Healthcare Access: Enhance access to healthcare services, particularly in rural and underserved areas, and reduce economic barriers to proper treatment.

AMR poses a significant global health challenge, necessitating a multifaceted and urgent response. This review has highlighted critical areas where advances in technology, innovative therapies, and policy interventions can make meaningful strides in combating this crisis. Key findings emphasize the importance of ASPs, which have proven effective in optimizing antibiotic use and reducing the misuse that drives resistance. Similarly, the integration of rapid diagnostics, such as CRISPR-based and next-generation sequencing tools, offers a powerful means of improving clinical outcomes by enabling precise and timely identification of resistant pathogens.

Emerging therapies like bacteriophage treatment and antimicrobial peptides demonstrate promising alternatives to traditional antibiotics, particularly in managing multidrug-resistant infections. Although challenges such as high costs and regulatory barriers persist, advancements in synthetic biology and delivery systems hold the potential to overcome these obstacles. In addition, anti-virulence strategies and the One Health approach underscore the importance of addressing resistance at the human, animal, and environmental interface.

The implications of this work extend beyond individual innovations, underscoring the need for a holistic approach that combines technological breakthroughs with robust global policies. Collaborative efforts, from international frameworks to local implementation, are essential in addressing disparities in resource distribution and regulatory capacities, especially in low- and middle-income countries.

While significant progress has been made, limitations remain. This study did not address all possible solutions or account for every regional disparity in AMR impact. Future research should explore these gaps, focusing on scalable solutions for under-resourced settings and sustainable practices to limit environmental dissemination of resistance.

In conclusion, tackling AMR demands a comprehensive strategy that balances innovation with accessibility, policy with practice, and immediate action with long-term sustainability. By integrating these efforts, the global community can strive to preserve the efficacy of antibiotics and secure public health for generations to come. This work underscores the collective responsibility of governments, researchers, healthcare professionals, and the public to act decisively against the escalating threat of AMR.

Conflict of Interest: No potential conflict of interest relevant to this article was reported.

Funding: The authors have no relevant financial or non financial competing interests to report.

References

Abdulaziz Alqahtani, Bacteriophage treatment as an alternative therapy for multidrug-resistant bacteria. Saudi Medical Journal Dec 2023, 44 (12) 1222-1231. https://doi.org/10.15537/smj.2023.44.12.20230366

Alkan, S., Koseoglu, H., & Cinar, H. (2022). Surveillance of antimicrobial resistance in Turkey: Current status and future directions. *Journal of Infection and Public Health*, 15(4), 456-464. https://doi.org/10.1016/j.jiph.2022.04.005

Allen, R. C., Popat, R., Diggle, S. P., & Brown, S. P. (2014). Targeting virulence: Can we make evolution-proof drugs? *Nature Reviews Microbiology*, *12*(4), 300–308. https://doi.org/10.1038/nrmicro3232

Antibiotic resistance threats in the United States; 2013. https://www.cdc. gov/drugresistance/pdf/ar-threats-2013-508.pdf. Accessed September 16, 2019.

Barlam, T. F., Cosgrove, S. E., Abbo, L. M., MacDougall, C., Schuetz, A. N., Septimus, E. J., ... & Weber, D. J. (2016). Implementing an antibiotic stewardship program: Guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America. *Clinical Infectious Diseases*, *62*(10), e51–e77. https://doi.org/10.1093/cid/ciw118

Baur, D., Gladstone, B. P., Burkert, F., Carrara, E., Foschi, F., Döbele, S., & Tacconelli, E. (2017). Effect of antibiotic stewardship on the incidence of infection and colonisation with antibiotic-resistant bacteria and Clostridium difficile infection: A systematic review and meta-analysis. *The Lancet Infectious Diseases*, *17*(9), 990–1001. https://doi.org/10.1016/S1473-3099(17)30325-0

Battah, B., & Donadu, M. G. (2024). "Quorum Sensing Inhibitors: An Alternative Strategy to Win the Battle against Multidrug-Resistant (MDR) Bacteria." *Molecules*, 29(15), 3466. https://doi.org/10.3390/molecules29153466

Berendonk, T. U., Manaia, C. M., Merlin, C., Fatta-Kassinos, D., Cytryn, E., Walsh, F., ... & Bürgmann, H. (2015). Tackling antibiotic resistance: the environmental framework. *Nature Reviews Microbiology*, 13(5), 310-317.

Blaskovich, M. A. T. (Ed.). (2020). *Antibiotics Special Issue: Challenges and Opportunities in Antibiotic Discovery and Development. ACS Infectious Diseases, 6(6), 1286–1288.* doi:10.1021/acsinfecdis.0c00331

Boehme CC, Nabeta P, Hillemann D, Nicol MP, Shenai S, Krapp F, Allen J, Tahirli R, Blakemore R, Rustomjee R, Milovic A, Jones M, O'Brien SM, Persing DH, Ruesch-Gerdes S, Gotuzzo E, Rodrigues C, Alland D, Perkins MD. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med. 2010 Sep 9;363(11):1005-15. doi: 10.1056/NEJMoa0907847.

Bolsoy, N., & Sevil, Ü. (2006). Sağlık-hastalık ve kültür etkileşimi. *Atatürk Üniversitesi Hemşirelik Yüksekokulu Dergisi, Vol. 9*(3).

Bush, K., & Bradford, P. A. (2020). Epidemiology of β-lactamase-producing pathogens. *Clinical Microbiology Reviews*, 33(2), e00047-19.

Chan, B. K., Turner, P. E., Kim, S., Mojibian, H., Elefteriades, J. A., & Narayan, D. (2018). Phage treatment of an aortic graft infected with *Pseudomonas aeruginosa*. *Evolution, Medicine, and Public Health*, 2018(1), 60-66.

Chen JS, Ma E, Harrington LB, Da Costa M, Tian X, Palefsky JM, Doudna JA. CRISPR-Cas12a target binding unleashes indiscriminate single-stranded DNase activity. Science. 2018 Apr 27;360(6387):436-439. doi: 10.1126/science.aar6245.

Chin C.D., Laksanasopin T., Cheung Y.K., Steinmiller D., Linder V., Parsa H., Wang J., Moore H., Rouse R., Umviligihozo G., et al. Microfluidics-based diagnostics of infectious diseases in the developing world. Nat. Med. 2011;17:1015–1019. doi: 10.1038/nm.2408.

Chindelevitch, L., Jauneikaite, E., Wheeler, N.E., Allel, K., Ansiri-Asafoakaa, B.Y., Awuah, W.A., Bauer, D.C., Beisken, S., Fan, K., Grant, G., Graz, M., Khalaf, Y., Liyanapathirana, V., Montefusco-Pereira, C., Mugisha, L., Naik, A., Nanono, S., Nguyen, A., Rawson, T., Reddy, K., Ruzante, J.M., Schmider, A., Stocker, R., Unruh, L., Waruingi, D., Graz, H., & van Dongen, M. (2022). Applying data technologies to combat AMR: Current status, challenges, and opportunities on the way forward. *arXiv*. Erişim tarihi: 26 Ocak 2025, https://arxiv.org/abs/2208.04683

Chinemerem Nwobodo D, Ugwu MC, Oliseloke Anie C, Al-Ouqaili MTS, Chinedu Ikem J, Victor Chigozie U, Saki M. Antibiotic resistance: The challenges and some emerging strategies for tackling a global menace. J Clin Lab Anal. 2022 Sep;36(9):e24655. doi: 10.1002/jcla.24655.

Cisek, A. A., Dąbrowska, I., Gregorczyk, K. P., & Wyżewski, Z. (2017). Phage therapy in bacterial infections treatment: One hundred years after the discovery of bacteriophages. *Current Microbiology*, 74(2), 277-283.

Czaplewski, L., Bax, R., Clokie, M., Dawson, M., Fairhead, H., Fischetti, V. A., ... & Rex, J. H. (2016). Alternatives to antibiotics—a pipeline portfolio review. *The Lancet Infectious Diseases, 16*(2), 239–251. https://doi.org/10.1016/S1473-3099(15)00466-1

Davey, P., Marwick, C. A., Scott, C. L., Charani, E., McNeill, A., Brown, E., ... & Wilcox, M. H. (2017). Interventions to improve antibiotic prescribing practices for hospital inpatients. *Cochrane Database of Systematic Reviews*, (2), CD003543. https://doi.org/10.1002/14651858.CD003543.pub4

Demirci, M., Yilmaz, E., & Kaya, O. (2021). High prevalence of carbapenem-resistant *Klebsiella pneumoniae* in Turkish hospitals: A national concern. *Clinical Microbiology and Infection*, 27(3), 435-439. https://doi.org/10.1016/j.cmi.2021.01.001

Didelot, X., Bowden, R., Wilson, D. J., Peto, T. E., & Crook, D. W. (2016). Transforming clinical microbiology with bacterial genome sequencing. *Nature Reviews Genetics, 13*(9), 601–612. https://doi.org/10.1038/nrg3226

Doğan, N., Şensoy, N., Temel, R.F., Küçükköse, F., Akyüz, H., Erdal, Y., Korkmaz, O.S.B., & Sayan, T.S. (2021). Aile sağlığı merkezlerinde çalışan hekimlerin akılcı antibiyotik kullanımı konusunda farkındalıkları ve etki eden faktörler. *Kocatepe Tıp Dergisi, Özel Sayı, Vol. 22*, 155-160.

Dunachie S.J., Day N.P., Dolecek C. The challenges of estimating the human global burden of disease of antimicrobial resistant bacteria. Curr. Opin. Microbiol. 2020;57:95–101. doi: 10.1016/j.mib.2020.09.013

Dyar, O. J., Huttner, B., Schouten, J., & Pulcini, C. (2017). What is antimicrobial stewardship? *Clinical Microbiology and Infection, 23*(11), 793-798. https://doi.org/10.1016/j.cmi.2017.08.026

Ellington MJ, Ekelund O, Aarestrup FM, Canton R, Doumith M, Giske C, Grundman H, Hasman H, Holden MTG, Hopkins KL, Iredell J, Kahlmeter G, Köser CU, MacGowan A, Mevius D, Mulvey M, Naas T, Peto T, Rolain JM, Samuelsen Ø, Woodford N. The role of whole genome sequencing in antimicrobial susceptibility testing of bacteria: report from the EUCAST Subcommittee. Clin Microbiol Infect. 2017 Jan;23(1):2-22. doi: 10.1016/j.cmi.2016.11.012.

Financial Times. (2023). Mass drug administration and AMR challenges in high-mortality regions. Erişim tarihi: 26 Ocak 2025, https://www.ft.com/content/38bfcbe6-4f7d-4a95-879c-12a988321862

Fitchett JR, Altun R. Antimicrobial resistance: opportunity for Europe to establish global leadership. The Lancet Infectious Diseases, 2015 Volume 16, Issue 4, 388 – 389

Fleitas Martínez, O., Cardoso, M. H., Ribeiro, S. M., & Franco, O. L. (2019). "Recent Advances in Anti-virulence Therapeutic Strategies With a Focus on Dismantling Bacterial Membrane Microdomains, Toxin Neutralization, Quorum-Sensing Interference, and Biofilm Inhibition." *Frontiers in Cellular and Infection Microbiology*, 9, 74. https://doi.org/10.3389/fcimb.2019.00074

Garvey M. Antimicrobial Peptides Demonstrate Activity against Resistant Bacterial Pathogens. Infect Dis Rep. 2023 Aug 14;15(4):454-469. doi: 10.3390/idr15040046.

Hancock, R. E., Haney, E. F., & Gill, E. E. (2016). The immunology of host defence peptides: Beyond antimicrobial activity. *Nature Reviews Immunology*, 16(5), 321-334.

Harun, M.G.D., Sumon, S.A., Hasan, I., Akther, F.M., Islam, M.S., & Anwar, M.M.U. (2024). Barriers, facilitators, perceptions and impact of interventions in implementing antimicrobial stewardship programs in hospitals of low-middle and middle countries: A scoping review. *Antimicrobial Resistance & Infection Control*, *Vol. 13*(1), 8. https://doi.org/10.1186/s13756-024-01369-6

Iskandar K., Molinier L., Hallit S., Sartelli M., Hardcastle T.C., Haque M., Lugova H., Dhingra S., Sharma P., Islam S., et al. Surveillance of antimicrobial resistance in low- and middle-income countries: A scattered picture. Antimicrob Resist. Infect. Control. 2021;10:1–13. doi: 10.1186/s13756-021-00931

İlhan, N., & Akhan, L.U. (2019). Kültürel özelliklerin sağlık üzerine etkileri. *İTOBİAD Kongre, II. İnsan ve Toplum Bilimleri Araştırmaları Kongresi.*

Ji S., An F., Zhang T., Lou M., Guo J., Liu K., Zhu Y., Wu J., Wu R. Antimicrobial peptides: An alternative to traditional antibiotics. Eur J Med Chem. 2024 Feb 5;265:116072. doi: 10.1016/j.ejmech.2023.116072.

Simpkin, V., Renwick, M., Kelly, R. Mossialos, E. Incentivising innovation in antibiotic drug discovery and development: progress, challenges and next steps. *J Antibiot* 70, 1087–1096 (2017). https://doi.org/10.1038/ja.2017.124

Kalli, M., Noutsopoulos, C., & Mamais, D. (2023). The fate and occurrence of antibiotic-resistant bacteria and antibiotic resistance genes during advanced wastewater treatment and disinfection: A review. *Water*, *15*(11), 2084. https://doi.org/10.3390/w15112084

Kanan, M., Ramadan, M., Haif, H., Abdullah, B., Mubarak, J., Ahmad, W., Mari, S., Hassan, S., Eid, R., Hasan, M., Qahl, M., Assiri, A., Sultan, M., Alrumaih, F., & Alenzi, A. (2023). Empowering low- and middle-income countries to combat AMR by minimal use of antibiotics: A way forward. *Antibiotics (Basel), Vol. 12*(10), 1504. https://doi.org/10.3390/antibiotics12101504

Kong, C., Neoh, H., & Nathan, S. (2016). "Targeting Staphylococcus aureus Toxins: A Potential Form of Anti-Virulence Therapy." Toxins, 8(3), 72. https://doi.org/10.3390/toxins8030072

Laxminarayan R., Duse A., Wattal C., Zaidi A.K., Wertheim H.F., Sumpradit N., Vlieghe E., Hara G.L., Gould I.M., Goossens H., Greko C., So A.D., Bigdeli M., Tomson G., Woodhouse W., Ombaka E., Peralta A.Q., Qamar F.N., Mir F., Kariuki S., Bhutta Z.A., Coates A., Bergstrom R., Wright G.D., Brown E.D., Cars O. Antibiotic resistance-the need for global solutions. Lancet Infect Dis. 2013 Dec;13(12):1057-98. doi: 10.1016/S1473-3099(13)70318-9.

Lei, J., Sun, L., Huang, S., Zhu, C., Li, P., He, J., ... & Nie, G. (2019). The antimicrobial peptides and their potential clinical applications. *American Journal of Translational Research*, *11*(7), 3919-3931. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6738436/

Lewis, K. (2020). "The discovery of antibiotics: A historical overview." *Clinical Microbiology Reviews*, 33(4), e00080-20.

Lin J., Du F., Long M, Li P. Limitations of Phage Therapy and Corresponding Optimization Strategies: A Review. Molecules. 2022 Mar 13;27(6):1857. doi: 10.3390/molecules27061857.

Liu, Y. Y., Wang, Y., Walsh, T. R., Yi, L. X., Zhang, R., Spencer, J., ... & Shen, J. (2016). Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. *The Lancet Infectious Diseases*, 16(2), 161-168.

Magana, M., Pushpanathan, M., Santos, A. L., Leanse, L., Fernandez, M., Ioannidis, A., ... & Tegos, G. P. (2020). The value of antimicrobial peptides in the age of resistance. *The Lancet Infectious Diseases*, *20*(9), e216-e230. https://doi.org/10.1016/S1473-3099(20)30327-3

Martínez, J. L., Coque, T. M., & Baquero, F. (2015). What is a resistance gene? Ranking risk in resistomes. *Nature Reviews Microbiology*, 13(2), 116-123.

Max, R., Rehman, S. (2023). Addressing antimicrobial resistance in low and middle-income countries: Current perspectives and future directions. *Environmental Science and Pollution Research*, 30, 29434–29445.

McCubbin KD, Anholt RM, de Jong E, Ida JA, Nóbrega DB, Kastelic JP, Conly JM, Götte M, McAllister TA, Orsel K, Lewis I, Jackson L, Plastow G, Wieden HJ, McCoy K, Leslie M, Robinson JL, Hardcastle L, Hollis A, Ashbolt NJ, Checkley S, Tyrrell GJ, Buret AG, Rennert-May E, Goddard E, Otto SJG, Barkema HW. Knowledge Gaps in the Understanding of Antimicrobial Resistance in Canada. Front Public Health. 2021 Oct 20;9:726484. doi: 10.3389/fpubh.2021.726484.

Michael, I., Rizzo, L., McArdell, C. S., Manaia, C. M., Merlin, C., Schwartz, T., Dagot, C., & Fatta-Kassinos, D. (2013). Urban wastewater treatment plants as hotspots for antibiotic-resistant bacteria and genes spread into the environment: A review. *Science of the Total Environment*, *447*, 345–360. https://doi.org/10.1016/j.scitotenv.2013.01.032

Milmo, S. (2019). Regulating pharmaceuticals in the environment. *Pharmaceutical Technology Europe*, *31*(4), 8–9. Retrieved from https://www.pharmtech.com

Murray, C. J. L., Ikuta, K. S., Sharara, F., Swetschinski, L., Aguilar, G. R., Gray, A., ... & Rao, P. (2022). Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. *The Lancet*, *399*(10325), 629-655. https://doi.org/10.1016/S0140-6736(21)02724-0

Mustafa M.I., Makhawi A.M. SHERLOCK and DETECTR: CRISPR-Cas Systems as Potential Rapid Diagnostic Tools for Emerging Infectious Diseases. J Clin Microbiol. 2021 Feb 18;59(3):e00745-20. doi: 10.1128/JCM.00745-20.

Nobrega, F. L., Costa, A. R., Kluskens, L. D., & Azeredo, J. (2018). Revisiting phage therapy: New applications for old resources. *Trends in Microbiology, 26*(8), 688–698. https://doi.org/10.1016/j.tim.2018.01.006

Okeke, I. N., Peeling, R. W., Goossens, H., Auckenthaler, R., Olmsted, S. S., de Lavison, J. F., ... & Nordqvist, K. (2011). Diagnostics as essential tools for containing antimicrobial resistance. *Drug Resistance Updates, 14*(2), 95–106. https://doi.org/10.1016/j.drup.2011.02.002

Outterson, K., et al. (2016). "Delinking Investment in Antibiotics from Sales: A Key Component of a Global Solution." *Clinical Infectious Diseases*, 62(S2), S81-S88.

Painter, C., Faradiba, D., Chavarina, K.K., Sari, E.N., Teerawattananon, Y., Aluzaite, K., & Ananthakrishnan, A. (2023). A systematic literature review of economic evaluation studies of interventions impacting antimicrobial resistance. *Antimicrobial Resistance & Infection Control, Vol. 12*(1), 69. https://doi.org/10.1186/s13756-023-01265-5

Panovska, A. P., & Hajrulai-Musliu, Z. (2024). Antibiotic resistance and aquatic systems: Importance in public health. *Water, 16*(17), 2362. https://doi.org/10.3390/w16172362

Piddock, L.J.V., Alimi, Y., Anderson, J. *et al.* Advancing global antibiotic research, development and access. *Nat Med* 30, 2432–2443 (2024). https://doi.org/10.1038/s41591-024-03218-w

Pirnay, J. P., Verbeken, G., Ceyssens, P. J., Huys, I., De Vos, D., Amadeus, G., ... & Merabishvili, M. (2019). The phage therapy paradigm: Pre-à-Porter or Sur-Mesure? *Pharmaceutical Research, 36*(4), 117. https://doi.org/10.1007/s11095-019-2617-x

Pokharel, S., Raut, S., & Adhikari, B. (2019). Tackling antimicrobial resistance in low-income and middle-income countries. *BMJ Global Health, Vol. 4*, e002104. https://doi.org/10.1136/bmjgh-2019-002104

Prestinaci F, Pezzotti P, Pantosti A. Antimicrobial resistance: a global multifaceted phenomenon. Pathog Glob Health. 2015;109(7):309. doi:10.1179/2047773215Y.0000000030

Rex, J. H., & Outterson, K. (2016). Antibiotic reimbursement in a model delinked from sales: A benchmark-based worldwide approach. *The Lancet Infectious Diseases*, *16*(4), 500-505. https://doi.org/10.1016/S1473-3099(16)00068-2

Ribeiro da Cunha B, Fonseca LP, Calado CRC. Antibiotic Discovery: Where Have We Come from, Where Do We Go? Antibiotics (Basel). 2019 Apr 24;8(2):45. doi: 10.3390/antibiotics8020045. PMID: 31022923; PMCID: PMC6627412.

Rony, M.K.K., Sharmi, P.D., & Alamgir, H.M. (2023). Addressing antimicrobial resistance in low and middle-income countries: Overcoming challenges and implementing effective strategies. *Environmental Science and Pollution Research, Vol. 30*, 101896–101902. https://doi.org/10.1007/s11356-023-29434-4

Schnall, J., Rajkhowa, A., Ikuta, K., Rao, P., & Moore, C.E. (2019). Surveillance and monitoring of antimicrobial resistance: Limitations and lessons from the GRAM project. *BMC Medicine, Vol. 17*(1), 176. https://doi.org/10.1186/s12916-019-1412-8

Schuts, E. C., Hulscher, M. E., Mouton, J. W., Verduin, C. M., Stuart, J. W., Overdiek, H. W., & Prins, J. M. (2016). Current evidence on hospital antimicrobial stewardship objectives: a systematic review and meta-analysis. *The Lancet Infectious Diseases*, 16(7), 847-856. https://doi.org/10.1016/S1473-3099(16)00065-7

Singh, S., Charani, E., Devi, S., Sharma, A., Edathadathil, F., Kumar, A., Warrier, A., Shareek, P.S., Jaykrishnan, A.V., & Ellangovan, K. (2021). A road-map for addressing antimicrobial resistance in low- and middle-income countries: Lessons learnt from the public-private participation and co-designed antimicrobial stewardship programme in the State of Kerala, India. *Antimicrobial Resistance & Infection Control, Vol. 10*(1), 32. https://doi.org/10.1186/s13756-020-00873-9

Sirwan Khalid Ahmed, Safin Hussein, Karzan Qurbani, Radhwan Hussein Ibrahim, Abdulmalik Fareeq, Kochr Ali Mahmood, Mona Gamal Mohamed, Antimicrobial resistance: Impacts, challenges, and future prospects, Journal of Medicine, Surgery, and Public Health, Volume 2, 2024,100081, ISSN 2949-916X, https://doi.org/10.1016/j.glmed .2024.100081.

Smith, A., & Team. (2023). Assessing antibiotic resistance in wastewater treatment. *Environmental Science & Technology*. Retrieved from USC Viterbi Magazine: https://magazine.viterbi.usc.edu

Sun Q, Shen L, Zhang BL, Yu J, Wei F, Sun Y, Chen W, Wang S. Advance on Engineering of Bacteriophages by Synthetic Biology. Infect Drug Resist. 2023 Mar 31;16:1941-1953. doi: 10.2147/IDR.S402962.

Turkish Ministry of Health. (2023). Rational Drug Use Action Plan. Available at: https://www.saglik.gov.tr

U.S. Food and Drug Administration (FDA). (2020) Limited Population Pathway for Antibacterial and Antifungal Drugs – the LPAD Pathway | FDA

Van Belkum, A., Soriaga, L. B., LaFave, M. C., Akella, S., Veyrieras, J. B., Barbu, E. M., ... & Dunne, W. M. (2019). Phylogenetic distribution of CRISPR-Cas systems in antibiotic-resistant *Pseudomonas aeruginosa*. *mBio*, 10(4), e01436-19.

Van Boeckel, TP, Brower, C., Gilbert, M., Grenfell, B. T., Levin, S. A., Robinson, T. P., ... & Laxminarayan, R. (2017). Global trends in antimicrobial use in food animals. *Proceedings of the National Academy of Sciences*, 114(18), 9347-9352.

Van Boeckel TP, Gandra S, Ashok A, Caudron Q, Grenfell BT, Levin SA, Laxminarayan R. Global antibiotic consumption 2000 to 2010: an analysis of national pharmaceutical sales data. Lancet Infect Dis. 2014 Aug;14(8):742-750. doi: 10.1016/S1473-3099(14)70780-7.

Van Dijck, C., Vlieghe, E., & Cox, J. A. (2018). Antibiotic stewardship interventions in hospitals in low-and middle-income countries: A systematic review. *Bulletin of the World Health Organization*, *96*(4), 266–280. https://doi.org/10.2471/BLT.17.203448

Van Santen, K. L., Edwards, J. R., Seibert, D. J., & McDonald, L. C. (2022). "Antimicrobial stewardship programs in hospitals: Implementation and impact." *Infection Control & Hospital Epidemiology*, *43*(3), 239-245. https://doi.org/10.1017/ice.2021.330

Ventola, C. L. (2015). "The antibiotic resistance crisis: part 1: causes and threats." *P&T*, 40(4), 277-283.

Verma, D. P., Tripathi, A. K., & Thakur, A. K. (2024). Innovative Strategies and Methodologies in Antimicrobial Peptide Design. *Journal of Functional Biomaterials*, *15*(11), 320. https://doi.org/10.3390/jfb15110320

Wernli, Didier & Jørgensen, Peter & Parmley, Elizabeth & Troell, Max & Majowicz, Shannon & Harbarth, Stephan & Léger, Anaïs & Lambraki, Irene & Graells, Tiscar & Henriksson, Patrik & Carson, Carolee & Cousins, Melanie & Ståhlgren, Gunilla & Mohan, Chadag & Simpson, Andrew & Wieland, Barbara & Pedersen, Karl & Schneider, Annegret & Chandy, Sujith & Pittet, Didier. (2020). Evidence for action: a One Health learning platform on interventions to tackle antimicrobial resistance. The Lancet Infectious Diseases. 20. 10.1016/S1473-3099(20)30392-3.

Woldegeorgis, B.Z., Kerbo, A.A., Obsa, M.S., & Mokonnon, T.M. (2023). A systematic review and meta-analysis of antimicrobial resistance knowledge, attitudes, and practices: Current evidence to build a strong national antimicrobial drug resistance narrative in Ethiopia. *PLoS One, Vol. 18*(6), e0287042. https://doi.org/10.1371/journal.pone.0287042

World Health Organization (WHO). The Global Action Plan on Antimicrobial Resistance, with an emphasis on a One Health approach. *WHO*; 2015. Available from: https://www.who.int/publications/i/item/9789241509763

World Health Organization (WHO) (2015). Global Action Plan on Antimicrobial Resistance. Global action plan on antimicrobial resistance

World Health Organization (WHO). (2019). "Global Antibiotic Research and Development Partnership (GARDP)." Retrieved from WHO.int.

World Health Organization. (2023). Antimicrobial resistance. Erişim tarihi: 21 Kasım 2023, https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance?utm_source=chatgpt.com

Zay Ya, K., Lambiris, M.J., Levine, G.A., Tediosi, F., & Fink, G. (2024). Coverage of policies to improve antimicrobial stewardship in human medicine in low and middle-income countries: Results from the Global Survey of Experts on Antimicrobial Resistance. *BMC Public Health, Vol. 24*(1), 2297. https://doi.org/10.1186/s12889-024-19542-2